Addition of histone deacetylase inhibitors in combination therapy

Journal of Clinical Oncology

Volumn 25, Issue 15, 2007, Pages 1955-1956

  Carraway, Hetty E ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE DERIVATIVE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPIRUBICIN; FR 901228; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINISTAT; ANTINEOPLASTIC ANTIBIOTIC; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR;

ACETYLATION; ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDITORIAL; EPIGENETICS; GENE EXPRESSION; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; METHYLATION; PRIORITY JOURNAL; PROSTATE TUMOR; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; NEOPLASM; NOTE; PATHOLOGY;

ANTIBIOTICS, ANTINEOPLASTIC; DNA TOPOISOMERASES, TYPE II; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPIRUBICIN; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; VALPROIC ACID;

EID: 34249930267     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.8293     Document Type: Editorial

References (21)

1. Rosato RR, Grant S: Histone deacetylase inhibitors: Insights into mechanisms of lethality. Expert Opin Ther Targets 9:809-824, 2005
2. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
3. Robertson KD, Ait-Si-Ali S, Yokochi T, et al: DNMT1 forms a complex with rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338-342, 2000
4. Sambucetti LC, Fischer DD, Zabludoff S, et al: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274:34940-34947, 1999
5. Kosugi H, Towatari M, Hatano S, et al: Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy. Leukemia 13:1316-1324, 1999
6. Marchion DC, Bicaku E, Daud AI, et al: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92:223-237, 2004
7. Catalano MG, Fortunati N, Pugliese M, et al: Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191:465-472, 2006
8. Kurz EU, Wilson SE, Leader KB, et al: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1:121-131, 2001
9. Tsai SC, Valkov N, Yang WM, et al: Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26:349-353, 2000
10. Dowdy SC, Jiang S, Zhou XC, et al: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5:2767-2776, 2006
11. Friedmann I, Atmaca A, Chow KU, et al: Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18:415-420, 2006
12. Nimmanapalli R, Fuino L, Stobaugh C, et al: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of bcr-abl-positive human acute leukemia cells. Blood 101:3236-3239, 2003
13. Ten Cate B, Samplonius DF, Bijma T, et al: The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 21:248-252, 2007
14. Marchion DC, Bicaku E, Daud AI, et al: In vivo synergy between topoisomerase II and histone deacetylase inhibitors: Predictive correlates. Mol Cancer Ther 4:1993-2000, 2005
15. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007
16. Gore SD, Baylin S, Sugar E, et al: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369, 2006
17. Xia Q, Sung J, Chowdhury W, et al: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237-7244, 2006
18. Münster P, Marchion D, Bicaku E, et al: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study. J Clin Oncol 25:1979-1985, 2007
19. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al: Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 2006
20. Michelotti A, Venturini M, Tibaldi C, et al: Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat 59:133-139, 2000
21. Rosenthal MA, Green M, Wiernik P, et al: Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: Phase II studies by the eastern cooperative oncology group. Am J Clin Oncol 21:509-512, 1998